Índice Bovespa

US Dollar vs BRL

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

RGLS Regulus Therapeutics Inc

2,42

0,15 (6,61%)

26 Abr 2024 - Fechado

Atrasado em 15 minutos

Form EFFECT - Notice of Effectiveness

Regulus Therapeutics (NASDAQ:RGLS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

Click aqui para mais gráficos Regulus Therapeutics.

Regulus Therapeutics (NASDAQ:RGLS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024

Click aqui para mais gráficos Regulus Therapeutics.

Notícias Regulus Therapeutics Inc

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
Quinta, 21 de Março de 2024 (1 mês atrás) • PR Newswire (US)

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
Terça, 12 de Março de 2024 (2 meses atrás) • PR Newswire (US)

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Terça, 12 de Março de 2024 (2 meses atrás) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Quinta, 18 de Janeiro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quinta, 18 de Janeiro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 17 de Janeiro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 17 de Janeiro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Sexta, 12 de Janeiro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Quarta, 10 de Janeiro de 2024 (4 meses atrás) • Edgar (US Regulatory)

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Terça, 2 de Janeiro de 2024 (4 meses atrás) • PR Newswire (US)

Form S-3 - Registration statement under Securities Act of 1933
Quarta, 27 de Dezembro de 2023 (4 meses atrás) • Edgar (US Regulatory)

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
Quarta, 22 de Novembro de 2023 (5 meses atrás) • PR Newswire (US)

Mais Notícias de Regulus Therapeutics Inc

Índice Bovespa

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições